Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Pharmos(PARS) -- Ignore unavailable to you. Want to Upgrade?

To: Omer Shvili who wrote (722)	5/5/1998 9:37:00 AM
From: yosi s	Respond to of 1491

Omer I agree with you post. But let me clarify my understanding of dosing and toxicity.and what is called therapeutic index. A medication can be safe but the range is important, the biggest the range the greater the margin of safety. this is part of reason to increase the dose. Though safety is done in phase 1 it is with fewer number, and healthy patient. Always a question is a drug safe in sick patient and in real life setting, when you get other medication. If you remember there was an anihistamine that was recalled off the market because when people took this medication with grapefruit juice some very rarely developed dangerous heart rythme. so after over than one year on the market it was withdrawn. As to increase efficacy with increase dosage. this will be looked as well, but more so to be able to plan for phase 3 trial. I guess that those are detail but very important technical detail. IPIC droped because they did not pay carefull attention to study design. Pars is being very carefull, and their dosing is very prudent. And I beleive that the medication HU211 is going to have a good safety profile. and if the placebo group is acting like a placebo group efficacy will be seen in phase 2 study,. SO I see HU 211 as a great potential product.